X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-10-29 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $6.72 | -11,447 | 7,077,560 | 0% | -$76,926 | ||||||
2024-10-31 | SCLX | Scilex Holding Co | Ji Henry | Exec Chairperson | P - Purchase | $0.94 | +8,888 | 680,884 | +1% | +$8,351 | ||||||
2024-10-28 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $28.39 | -25,000 | 581,324 | -4% | -$709,750 | ||||||
| M | 2024-10-28 | GLUE | Monte Rosa Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $9.44 | -157,895 | 5,652,922 | -3% | -$1,491,041 | |||||
2024-10-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $6.06 | -1,621 | 390,063 | 0% | -$9,823 | ||||||
| M | 2024-10-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $6.03 | -9,102 | 304,091 | -3% | -$54,905 | |||||
2024-10-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $6.06 | -2,688 | 520,745 | -1% | -$16,289 | ||||||
2024-10-28 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $6.06 | -1,632 | 321,907 | -1% | -$9,890 | ||||||
2024-10-29 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $10.74 | -9,200 | 452,059 | -2% | -$98,788 | ||||||
2024-10-29 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | VP, Finance | S - Sale | $10.74 | -553 | 39,443 | -1% | -$5,938 | ||||||
2024-10-29 | SCLX | Scilex Holding Co | Shah Jaisim | See Remarks | P - Purchase | $0.99 | +32,000 | 265,215 | +14% | +$31,670 | ||||||
| D | 2024-10-24 | RXRX | Recursion Pharmaceuticals, Inc. | Marriott Tina | Pres, COO | S - Sale+OE | $6.31 | -6,000 | 521,138 | -1% | -$37,855 | |||||
2024-10-23 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $29.53 | -4,361 | 322,878 | -1% | -$128,780 | ||||||
2024-10-23 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $29.53 | -3,189 | 134,971 | -2% | -$94,171 | ||||||
2024-10-23 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $29.53 | -2,740 | 142,186 | -2% | -$80,912 | ||||||
2024-10-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $43.09 | -2,261 | 159,483 | -1% | -$97,429 | ||||||
2024-10-22 | TECX | Tectonic Therapeutic, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $33.59 | +300,000 | 4,593,121 | +7% | +$10,077,000 | ||||||
| D | 2024-10-21 | IKT | Inhibikase Therapeutics, Inc. | Bellini Roberto | Dir | P - Purchase | $1.37 | +1,460,000 | 1,460,000 | New | +$2,000,200 | |||||
| D | 2024-10-21 | IKT | Inhibikase Therapeutics, Inc. | Kush Arvind | Dir | P - Purchase | $1.37 | +145,000 | 145,000 | New | +$198,650 | |||||
| D | 2024-10-21 | IKT | Inhibikase Therapeutics, Inc. | Munshi Amit | Dir | P - Purchase | $1.37 | +365,000 | 365,000 | New | +$500,050 | |||||
| M | 2024-10-21 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.77 | -3,428 | 17,823,982 | 0% | -$2,649 | |||||
2024-10-21 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.78 | -9,752 | 742,678 | -1% | -$7,597 | ||||||
| M | 2024-10-21 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.77 | -965 | 70,715 | -1% | -$746 | |||||
| M | 2024-10-21 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.77 | -1,401 | 503,002 | 0% | -$1,083 | |||||
| D | 2024-10-22 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $89.69 | -1,500 | 0 | -100% | -$134,535 | |||||
| D | 2024-10-18 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale+OE | $27.69 | -40,000 | 2,438,411 | -2% | -$1,107,600 | |||||
| D | 2024-10-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $115.39 | -42,000 | 90,383 | -32% | -$4,846,508 | |||||
| D | 2024-10-21 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $6.50 | -2,923 | 10,979 | -21% | -$19,000 | |||||
| D | 2024-10-18 | AURA | Aura Biosciences, Inc. | Feder Julie B | CFO | S - Sale+OE | $12.03 | -25,131 | 134,276 | -16% | -$302,361 | |||||
2024-10-17 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $1.62 | -1,078,600 | 4,254,302 | -20% | -$1,747,332 | ||||||
| D | 2024-10-18 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale+OE | $12.04 | -24,992 | 461,259 | -5% | -$300,839 | |||||
| DM | 2024-10-17 | NMRA | Neumora Therapeutics, Inc. | Fust Matthew K | Dir | S - Sale+OE | $17.03 | -21,788 | 20,100 | -52% | -$370,962 | |||||
2024-10-16 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $28.79 | -9,095 | 994,789 | -1% | -$261,845 | ||||||
2024-10-16 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $28.79 | -3,188 | 365,144 | -1% | -$91,783 | ||||||
2024-10-18 | SCLX | Scilex Holding Co | Followwill Dorman | Dir | P - Purchase | $0.99 | +1,000 | 2,300 | +77% | +$990 | ||||||
2024-10-18 | SCLX | Scilex Holding Co | Chun Jay | Dir | P - Purchase | $0.95 | +5,000 | 112,511 | +5% | +$4,750 | ||||||
2024-10-16 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $28.79 | -2,860 | 327,239 | -1% | -$82,339 | ||||||
2024-10-16 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $28.79 | -3,271 | 335,343 | -1% | -$94,172 | ||||||
| M | 2023-12-27 | ENGN | Engene Holdings Inc. | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% | P - Purchase | $6.40 | +470,633 | 6,236,565 | +8% | +$3,012,674 | |||||
| DM | 2024-10-16 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $40.86 | -35,000 | 220,937 | -14% | -$1,430,100 | |||||
| D | 2024-10-16 | VCEL | Vericel Corp | Gilman Steven C | Dir | S - Sale+OE | $41.36 | -5,833 | 11,000 | -35% | -$241,253 | |||||
2024-10-17 | SCLX | Scilex Holding Co | Wu Yue Alexander | Dir | P - Purchase | $0.95 | +20,000 | 25,000 | +400% | +$18,992 | ||||||
2024-10-17 | SCLX | Scilex Holding Co | Lemus David | Dir | P - Purchase | $0.90 | +2,000 | 2,000 | New | +$1,800 | ||||||
2024-10-17 | SCLX | Scilex Holding Co | Ji Henry | Exec Chairperson | P - Purchase | $0.97 | +10,000 | 671,996 | +2% | +$9,710 | ||||||
| D | 2024-10-16 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir | P - Purchase | $15.96 | +3,133 | 533,424 | +1% | +$49,993 | |||||
2024-10-15 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $6.67 | -11,447 | 7,089,007 | 0% | -$76,326 | ||||||
2024-10-16 | SCLX | Scilex Holding Co | Shah Jaisim | See Remarks | P - Purchase | $0.99 | +30,000 | 233,215 | +15% | +$29,751 | ||||||
2024-10-16 | SCLX | Scilex Holding Co | Ma Stephen Hoi | CFO | P - Purchase | $0.97 | +6,700 | 22,840 | +42% | +$6,499 | ||||||
2024-10-16 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $9.85 | -7,383 | 121,132 | -6% | -$72,723 | ||||||
| DM | 2024-10-15 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $53.50 | -20,000 | 173,756 | -10% | -$1,070,059 | |||||
2024-10-15 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $0.56 | -31,897 | 1,025,816 | -3% | -$17,926 | ||||||
| D | 2024-10-14 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale+OE | $26.27 | -51,110 | 160,260 | -24% | -$1,342,752 | |||||
| D | 2024-10-14 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $49.49 | -16,666 | 264,408 | -6% | -$824,804 | |||||
| D | 2024-10-16 | ZIVO | Zivo Bioscience, Inc. | Payne John Bernard | Pres, CEO | P - Purchase | $15.76 | +6,343 | 7,909 | +405% | +$99,966 | |||||
| D | 2024-10-14 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $46.28 | -1,089 | 62,597 | -2% | -$50,399 | |||||
| D | 2024-10-14 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $46.28 | -4,293 | 312,162 | -1% | -$198,680 | |||||
| M | 2024-10-11 | CADL | Candel Therapeutics, Inc. | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.03 | -40,412 | 6,053,781 | -1% | -$243,834 | |||||
| D | 2024-10-11 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $50.34 | -50,000 | 132,320 | -27% | -$2,517,055 | |||||
| D | 2024-10-11 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $50.36 | -30,000 | 816,622 | -4% | -$1,510,773 | |||||
| D | 2024-10-11 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $50.30 | -10,000 | 98,932 | -9% | -$502,979 | |||||
| D | 2024-10-11 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale+OE | $50.17 | -6,000 | 45,634 | -12% | -$301,027 | |||||
| D | 2024-10-10 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $8.10 | -5,000 | 120,695 | -4% | -$40,496 | |||||
| M | 2024-10-09 | NMRA | Neumora Therapeutics, Inc. | Lenz Robert A. | Head of R, D | S - Sale | $15.06 | -13,823 | 314,706 | -4% | -$208,110 | |||||
2024-10-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $41.81 | -856 | 73,397 | -1% | -$35,791 | ||||||
2024-10-09 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $29.56 | -5,162 | 338,614 | -2% | -$152,589 | ||||||
2024-10-09 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $29.56 | -4,460 | 1,003,884 | 0% | -$131,838 | ||||||
| DM | 2024-10-08 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $6.34 | -30,000 | 1,450,881 | -2% | -$190,131 | |||||
| D | 2024-10-08 | SRRK | Scholar Rock Holding Corp | Myles Edward H | COO, CFO | S - Sale+OE | $34.90 | -37,187 | 161,088 | -19% | -$1,297,659 | |||||
| D | 2024-10-08 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $4.53 | -1,406 | 48,623 | -3% | -$6,369 | |||||
2024-10-08 | RVMD | Revolution Medicines, Inc. | Weber Barbara | Dir | S - Sale | $48.02 | -5,200 | 13,065 | -28% | -$249,716 | ||||||
| DM | 2024-10-08 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $53.29 | -20,000 | 676,744 | -3% | -$1,065,743 | |||||
2024-10-08 | WINT | Windtree Therapeutics Inc /de/ | Fraser Craig | Pres, CEO | P - Purchase | $0.91 | +5,431 | 8,639 | +169% | +$4,942 | ||||||
2024-10-07 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $109.21 | -7,098 | 588,800 | -1% | -$775,154 | ||||||
| D | 2024-10-07 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $109.27 | -5,000 | 28,623 | -15% | -$546,353 | |||||
2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | Mostafa Adam S. | CFO | S - Sale | $0.55 | -230,645 | 0 | -100% | -$126,901 | ||||||
2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | Baldry Mark | Chief Commercial Officer | S - Sale | $0.58 | -11,127 | 48,509 | -19% | -$6,506 | ||||||
2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $0.55 | -239,436 | 1,057,713 | -18% | -$131,522 | ||||||
2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | Dibiase Mary | COO | S - Sale | $0.57 | -67,695 | 452,060 | -13% | -$38,329 | ||||||
2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.56 | -76,920 | 388,026 | -17% | -$43,306 | ||||||
| D | 2024-10-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.35 | -306 | 6,046 | -5% | -$2,555 | |||||
| D | 2024-10-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $8.35 | -1,217 | 30,237 | -4% | -$10,163 | |||||
| D | 2024-10-07 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $60.12 | -715 | 9,505 | -7% | -$42,986 | |||||
| D | 2024-10-07 | SRRK | Scholar Rock Holding Corp | Myles Edward H | COO, CFO | S - Sale+OE | $26.56 | -206,240 | 161,088 | -56% | -$5,477,546 | |||||
| D | 2024-10-07 | SRRK | Scholar Rock Holding Corp | Sacco Tracey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $25.62 | -30,000 | 49,285 | -38% | -$768,677 | |||||
2024-10-07 | SRRK | Scholar Rock Holding Corp | Akkaraju Srinivas | Dir | S - Sale | $29.25 | -1,175,713 | 11,905,005 | -9% | -$34,385,673 | ||||||
| D | 2024-10-07 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Chief Medical Officer | S - Sale+OE | $27.21 | -109,375 | 72,855 | -60% | -$2,976,468 | |||||
2024-10-02 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $56.26 | -6,665 | 274,128 | -2% | -$374,954 | ||||||
2024-10-02 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $56.23 | -40,000 | 1,354,487 | -3% | -$2,249,307 | ||||||
| DM | 2024-10-02 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.12 | -40,000 | 762,656 | -5% | -$244,800 | |||||
2024-10-03 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.81 | -940 | 17,827,410 | 0% | -$766 | ||||||
2024-10-03 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.81 | -377 | 504,403 | 0% | -$307 | ||||||
2024-10-03 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.81 | -1,493 | 752,430 | 0% | -$1,216 | ||||||
2024-10-03 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.81 | -301 | 71,680 | 0% | -$245 | ||||||
| D | 2024-10-02 | VCEL | Vericel Corp | Gilman Steven C | Dir | S - Sale+OE | $40.35 | -5,833 | 11,000 | -35% | -$235,362 | |||||
2024-10-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $43.21 | -3,310 | 84,585 | -4% | -$143,028 | ||||||
| D | 2024-10-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $43.21 | -13,605 | 481,918 | -3% | -$587,886 | |||||
2024-10-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $43.21 | -6,865 | 161,744 | -4% | -$296,644 | ||||||
2024-10-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $43.21 | -3,104 | 75,289 | -4% | -$134,127 | ||||||
| M | 2024-10-01 | CADL | Candel Therapeutics, Inc. | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.93 | -35,002 | 6,094,193 | -1% | -$242,642 | |||||
2024-10-01 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $6.22 | -11,447 | 7,098,428 | 0% | -$71,150 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |